GSK’s Bexsero, Shingrix to pass $1B sales mark by 2022: report
admin 20th June 2017 Uncategorised 0A key pickup from its massive Novartis asset swap, GlaxoSmithKline’s meningitis B shot Bexsero has been a standout performer in recent quarters. That’s not set to change, according to an analyst group, which predicted this week that the shot and pipeline vaccine Shingrix will each haul in more than $1 billion by 2022.
More: GSK’s Bexsero, Shingrix to pass B sales mark by 2022: report
Source: fierce